‘Stem Cell and Tissue Engineering market to be worth $10 billion by 2013’ says visiongain report

‘Stem Cell and Tissue Engineering market to be worth $ 10 billion by 2013’ says visiongain report

London, UK (PRWEB) June 10, 2004

Tissue engineering is the manufacturing of complete tissues outside of the body ready for future transplant use. This technology is available with several types of replacement skin, cartilage, regeneration of bone and other connective structural substitutes. The estimated market for the future of tissue engineered products are worth approximately $ 5 billion worldwide by 2013.

Tissue Engineering and Stem Cell Technology have had the capability to reform the medical market and have been recognised for some time. Theoretically, to put stem cells into a damaged heart may be simple but to persuade it to transform into functioning heart muscle is more difficult because it can transform itself into several things and can end up becoming stomach cells as opposed to heart muscle.

Dr Ray Scraggs, PhD, a leading certified Senior Industry Analyst, believes this market has huge revenues yet to be invested in by pharmaceutical companies and has the potential to grow in excess of $ 10 billion. He states that, “Stem cell technology has applications over such a wide range of diseases that the potential for this market will be huge. Undoubtedly, the medical use of stem cells will revolutionise medicine and any company that can successfully develop this technology will be guaranteed substantial financial rewards.”

This engineering of technology will have researchers investing in two highly lucrative markets and includes executives, investors, venture capitalists, business development managers and analysts looking into the following key areas:

1.The physiology behind stem cell technology

2.Over 100 companies involved and a survey of the principle companies in stem cell development

3.An examination of the products in development & the likely clinical areas for future treatments

4.Assessment of the future markets delivered to you today

5.An examination of the ethical and regulatory aspects behind stem cell research

6.The financial position of the market as it stands and future projections of growth

The current market has grown rapidly since the isolation of embryonic stem cells in 1998. “Recent scientific developments have made this field much more interesting to investors, especially as possible new medical treatments become more likely. However, realistically it may take another 10 years or more before stem cell technology becomes common place” says Dr Scraggs.

This is a multifaceted role for stem cells where a range of diseases could help account to this growth in potential and may offer treatments for:

1.Parkinson’s Disease

2.Diabetes

3.Chronic Heart Disease

4.Kidney Disease

5.Liver Failure

6.Cancer

7.Spinal Cord Injury

8.Multiple Sclerosis

9.Alzheimer’s Disease

10.Gene Therapy

All companies within this field are well aware of the difficulties and are adapting their working practice towards the long haul. This has resulted in many stem cell companies now investing in other areas to ensure some form of income before stem cell therapy becomes readily available.

Visiongain have recently released their report entitled Tissue Engineering and Stem Cell Technology Report 2003 – 2013. Please see full table of content below. For further information please email senh.ip@visiongain.com

Review of Contents:

1.Introduction

1.1 Background

1.2 Stem Cell Background

Table 1.1, Embryonic Germ Layers from which Differentiated Tissue Develops

1.3 Progenitor or Precursor Cell

1.4 The Human Embryonic Stem (ES) Cell

1.5 Major Questions Concerning Human ES Cells

1.6 The Human Embryonic Germ (EG) Cell

1.7 The Human Adult Stem Cell

1.8 Evidence for the Presence of Adult Stem Cells

1.9 Adult Stem Cell Plasticity

1.10 The Normal Differentiation Pathways of Adult Stem Cells

1.11 Adult Stem Cell Plasticity and Transdifferentiation

1.12 Major Questions Concerning Human Adult Stem Cells

1.13 Haematopoietic Stem Cells (HSC)

1.14 Sources of Haematopoietic Stem Cells

1.14.1 Bone Marrow

1.14.2 Peripheral Blood

1.14.3 Umbilical Cord Blood

1.14.4 Foetal Haematopoietic System

1.14.5 Embryonic Stem Cells and Embryonic Germ Cells

1.15 The Clinical Uses of Haematopoietic Stem Cells

1.15.1 Leukaemia and Lymphoma

1.15.2 Inherited Blood Disorders

1.15.2 Haematopoietic Stem Cell Rescue in Cancer Chemotherapy

1.15.3 Graft-Versus-Tumour Treatment of Cancer

1.15.4 Other Applications of Haematopoietic Stem Cells

1.16 Stem Cell Culture

1.17 The Identification of ES Cells

1.18 The Directed Differentiation of Stem Cells in Vitro

1.19 Stanford Researchers Isolate Protein Needed For Stem Cell Maintenance

1.20 Key definitions

1.21 Glossary

2. Potential Stem Cell Therapies

2.1 Stem Cell Use in Drug Testing

2.2 Stem Cell Use in Gene Therapy

2.3 Transgene Stem Cell Therapy Clinical Trials

2.4 Embryonic Stem Cells in Gene Therapy

2.5 Disease Treatment and the Clinical Use of Stem Cell Technology

2.6 Stem Cells and Diabetes

2.7 The Development of Stem Cell based Therapies for Diabetes

2.8 Stem Cells and the Nervous System

2.9 Parkinson’s Disease

2.10 Spinal Cord Injury

2.11 Multiple Sclerosis

2.12 Stem Cells and Heart Disease

2.13 Adult Stem Cells and Heart Disease

2.14 Embryonic Stem (ES) Cells in Heart Disease

2.15 In Vitro Stem Cell Organ Formation

2.16 Human Stem Cell Safety

3. The Market for Tissue Engineering Products

3.1 The History and Background of Tissue Engineering

3.2 Stem Cells and the Future of Tissue Engineering

3.3 Research Trends

3.4 Industry Developments

3.5 Market Strategies

3.6 Products

3.7 The Market for Tissue Engineering Products

3.8 The History of Artificial Skin

3.9 Artificial Skin and Skin Replacement in Practice

3.10 Artificial Skin Products

Table 3.1, Companies and Products in the Artificial Skin Market, 2003

3.10.1 TransCyte

3.10.2 Integra

3.10.3 Dermagraft

3.10.4 Apligraf

3.10.5 Composite Cultured Skin

3.11 The World Market for Artificial Skin

Table 3.1, The World Market for Artificial Skin ($ m), 2001-2008

3.12 The Potential Market for Tissue Engineered Bone, Other Structural Treatments and Wound Management

3.13 Companies in the Market

Table 3.2, Companies Focusing on Structural Tissue Engineering, 2003

Table 3.3, Companies Focusing on Metabolic Tissue Engineering, 2003

Table 3.4, Companies with Services for Tissue Engineering, 2003

4. Stem Cell Companies and Products in Development

Table 4.1, UK Companies and Areas of Research Focus, 2003

4.1 Intercytex Limited

4.2 Epistem

4.3 CereStem Ltd

4.4 Axordia Ltd

4.5 ReInnervate

4.6 Magnecell

4.7 RegenTec

4.8 CellFactors

4.9 ReNeuron

4.10 PPL Therapeutics

4.11 Geron

Table 4.2, Geron’s Cell Lines registered at NIH, 2003

4.12 Stem Cell Inc.

4.13 Aastrom Biosciences Inc

Table 4.2, Aastrom Product Line related to Stem Cells, 2003

4.14 Advanced Cell Technology

4.15 VistaGen

4.16 BresaGen

4.17 Companies In Brief

4.18 ReNeuron and VistaGen Announce Broad Stem Cell Drug Discovery Alliance

Table 4.3, The Top 100 Stem Cell Companies Worldwide, 2003

5. The Regulatory Issues of Stem Cell Research

5.1 Regulation in the USA

5.2 Regulation in the United Kingdom

5.3 Regulation in the European Union

5.4 Regulation in Other European States

5.5 Regulation in Sweden

5.6 European Summary

5.7 Regulation in Australia

5.8 Regulation in Canada

5.9 Regulation in Japan

5.10 Regulation in Israel

5.11 Regulation in China

5.12 Regulation in Singapore

5.13 Regulation in India

5.14 Companies and Labs with Stem Cell Lines and the NIH

Table 5.1, Laboratory Owned Stem Cell Lines, 2003

5.15 The UK Stem Cell Bank

5.16 Future Regulation

5.17    President George Bush’s Speech on Stem Cell Research in Full, August 9, 2001

6.The Market Potential of Stem Cell Technology

Companies involved in stem cell technology

Companies mentioned in this report includes:

COMPANY

StemCells Inc

Stem Cell Sciences Ltd

Aastrom Biosciences Inc

Neuronyx Corp

Osiris Therapeutics

Paradigm Genetics

Large Scale Biology Corp

Macropore Biosurgery Inc

Nexell Therapeutics

StemCell Technologies

MultiCell Technologies Inc

Aegera Therapeutics Inc

Galapagos Genomics

Genzyme Biosurgery

Lifecell Inc

MorphoGen Pharmaceuticals

Curis Inc

Acorda Therapeutics Inc

NeuralStem Inc

NeuroNova AB

Iceni BioDiscovery

CellGenix GmbH

Cytonet

Q MED AB

TiGenix

Artecel Sciences Inc

Biotissue Technologies AG

IBAT

Ixion Biotechnology

Modex Therapeutics

Orbus Medical Technologies

StemCo Biomedical Inc

StemSource Inc

Vitro Diagnostics Inc

Hitachi Medical Corp

Verigen

Vivalis

Advanced Cell Technology

Alpha Cord

American Cord Blood Inst

BioCell

BirthCells Technology

California Cryobank

Cells for Life Ltd

CorCell

Cord Blood Registry

CORD Inc

Cryo-Cell Europe N.V.

Cryo-Cell International

Cryobanks International

CryoLIFE

Cytomatrix LLC

FamilyLink

Gamida-Cell

Kourion

Lifebank

Lifebank Cryogenics Corp

Lifecord

New England Cord Blood Bank

Newborn Blood Banking Inc

Securacell Inc

Stem Cell Inst

StemCyte

UK Cord Blood Bank

ViaCord

Vita 34

ViaCell Inc

PPL Therapeutics plc

Cue Therapeutics

Innogenetics

NeoTherapeutics Inc

ProChon Biotech Ltd

Bioheart Inc

BresaGen Ltd

CyThera Inc

ES Cell International Pte Ltd

Geron Corp

IsoTis

Quark Biotech Inc

Cardion AG/Cardion Pharma Inc

Vistagen Inc

Layton Bioscience Inc

Ortec

Incara Pharmaceuticals Corp

ReNeuron Holdings plc

Endovasc Ltd Inc

Intercytex Ltd

Infigen Inc

Anthrogenesis Corp

Diacrin Inc

Alexion Pharmaceuticals

Hybrid Organ GmbH

Nephros Therapeutics Inc

Novo Nordisk B

Kaleidos Pharma

Advanced Tissue Sciences

Celmed BioSciences

Develogen

Hemosol Inc

Integra Lifesciences

NovaStem

About visiongain:

Visiongain is one of the fastest growing and most innovative independent media companies in Europe today. Based in London, UK, visiongain produce a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Financial markets, the Pharmaceutical, Telecoms industries and currently the Defence sector. Visiongain publish reports produced by their in-house analysts of qualified experts in their field. Visiongain have firmly established themselves as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Visiongain also have an event division, b2b Conferences, works in tandem with their analytical reports to provide a forum for key issues within the Telecoms and Pharmaceutical professionals.

For information:http://www.visiongain.com


Contact: Senh.Ip@visiongain.com mailto:Senh_Ip@visiongain.com

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Tags: 2013’, Billion, Cell, Engineering, Market, Report, Says, Tissue, visiongain, Worth, ‘Stem